Pieris Pharmaceuticals Inc (NASDAQ:PIRS) saw a downside of -5.38% to $0.31 after subtracting -$0.01 on Tuesday. The 5-day average trading volume is 673,128 shares of the company’s common stock. It has gained $0.3400 in the past week and touched a new high 3 times within the past 5 days. An average of 1,202,167 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 3,591,929.
PIRS’s 1-month performance is -6.53% or -$0.0195 on its low of $0.2900 reached on 08/28/23. The company’s shares have touched a 52-week low of $0.16 and high of $1.97, with the stock’s rally to the 52-week high happening on 02/02/23. YTD, PIRS has lost -70.43% or -$0.7305 and has reached a new high 12 times. However, the current price is down -84.39% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
PIRS stock has a beta of 0.75. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 0.92 while the price-to-book (PB) in the most recent quarter is 0.75.
Pieris Pharmaceuticals Inc’s quick ratio for the period ended June 30 was 1.93, with the current ratio over the same period at 1.93. As well, the company’s long term debt to equity for the quarter ending June 30 was 0.29, while the total debt to equity was 0.32. In terms of profitability, the gross margin trailing 12 months is 92.01%. The trailing 12-month EBITDA margin is -157.11% while for the period ending June 30, Pieris Pharmaceuticals Inc’s operating margin was -111.83%. The firm’s gross profit as reported stood at $69.38 million against revenue of $25.9 million.
Earnings Surprise
For the quarterly period ending June 30 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 359.8% to $3.98 million, while revenue of -$13.18 million was 431.16% off the previous quarter. Analysts expected PIRS to announce -$0.16 per share in earnings in its latest quarter, but it posted $0.05, representing a 131.20% surprise. EBITDA for the quarter stood at more than $2.82 million. PIRS stock balance sheet for the quarter ending June 30 shows that total liabilities totaled 47.05 million, with total debt at $12.83 million. Shareholders hold equity totaling $98.85 million.
Let’s look briefly at Pieris Pharmaceuticals Inc (PIRS) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 25 September was 44.07% to suggest the stock is trending Neutral, with historical volatility in this time period at 44.00%.
The stock’s 5-day moving average is $0.3197, reflecting a -1.43% or -$0.0045 change from its current price. PIRS is currently trading -10.55% above its 20-day SMA, -62.20% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +65.33% and SMA200 by-68.09%.
Stochastic %K and %D was 39.74% and 45.10% and the average true range (ATR) pointed at 0.0274. The RSI (14) points at 47.74%, while the 14-day stochastic is at 23.08% with the period’s ATR at 0.0318. The stock’s 9-day MACD Oscillator is pointing at -0.0009 and -0.0005 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Pieris Pharmaceuticals Inc (NASDAQ: PIRS), Robert W. Baird upgraded it to an Outperform rating. They previously had a Neutral rating on the stock. Analysts offering their rating for PIRS stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate PIRS as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 1 have offered a “buy” rating.
What is PIRS’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $7.00 and a high of $7.00, with their median price target at $7.00. Looking at these predictions, the average price target given by analysts is for Pieris Pharmaceuticals Inc (PIRS) stock is $7.00.
